Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?

Atherosclerosis is a complex process mediated by leukocytes, macrophages and various inflammatory markers. Galectin-3 is secreted by activated macrophages and is involved in cardiac fibrosis, cardiac remodeling, and inflammation. The present study aimed to determine the relationship between the pres...

Full description

Saved in:
Bibliographic Details
Published in:Journal of investigative medicine 2016-03, Vol.64 (3), p.764-770
Main Authors: Aksan, Gökhan, Gedikli, Ömer, Keskin, Kudret, Nar, Gökay, İnci, Sinan, Yıldız, Süleyman Sezai, Kaplan, Özgür, Soylu, Korhan, Kılıçkesmez, Kadriye Orta, Şahin, Mahmut
Format: Article
Language:English
Subjects:
Atherosclerosis
Atherosclerosis - blood
Biomarkers
Biomarkers - blood
C-Reactive Protein - metabolism
Cardiovascular disease
Case-Control Studies
Coronary Angiography
Coronary Artery Disease - blood
Female
Galectin 3 - blood
Humans
Inflammation
Logistic Models
Male
Middle Aged
Proteins
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973
cites cdi_FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973
container_end_page 770
container_issue 3
container_start_page 764
container_title Journal of investigative medicine
container_volume 64
creator Aksan, Gökhan
Gedikli, Ömer
Keskin, Kudret
Nar, Gökay
İnci, Sinan
Yıldız, Süleyman Sezai
Kaplan, Özgür
Soylu, Korhan
Kılıçkesmez, Kadriye Orta
Şahin, Mahmut
description Atherosclerosis is a complex process mediated by leukocytes, macrophages and various inflammatory markers. Galectin-3 is secreted by activated macrophages and is involved in cardiac fibrosis, cardiac remodeling, and inflammation. The present study aimed to determine the relationship between the presence and severity of coronary artery disease (CAD) and serum galectin-3 levels. The study included 82 patients with CAD confirmed via coronary angiography and 82 healthy participants as control group. Angiographic CAD was defined as ≥50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score; and the serum galectin-3 levels were measured via ELISA. Serum galectin-3 levels were significantly higher in the patient group with CAD than in the control group (12.96±4.92 vs 5.52±1.9 ng/mL, p
doi_str_mv 10.1136/jim-2015-000041
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768561776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1136_jim-2015-000041</sage_id><sourcerecordid>1768561776</sourcerecordid><originalsourceid>FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973</originalsourceid><addsrcrecordid>eNqFkMtKxDAUhoMo3tfuJOBGxDq5NGmyEhm8geBGd0JJ4ql2bJsx6Sxm50P4hD6JGTqKCGIWyQn58p_kQ2iPkhNKuRxN6jZjhIqMpJHTFbRJC6IyxWSxmmqiaCaE0htoK8YJIUwKzdbRBpOaMkL0Jnq4jvjJNOD6uss4NtjWvjXhBcJx2kwbM4fw8fbuA7a-f05V3eH-GfA0QITOAfYVdj74zoQ5Nukk-OiaxVzH0x20Vpkmwu5y3Ub3F-d346vs5vbyenx2k1muiz6zAEAcJVazR0akUMZRznPldJVTY7RSQuc5ySudM5KDs0JzbriuDLVgdMG30eGQOw3-dQaxL9s6Omga04GfxZIWUglJi0Im9OAXOvGz0KXXJUpJzQVnJFGjgXLpIzFAVU5DnbTMS0rKhfgyiS8X4stBfLqxv8yd2RYev_kv0wk4HoBonuBH0z_zjgbctpN_m38CmFuZvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786935320</pqid></control><display><type>article</type><title>Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?</title><source>Criminology Collection</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><creator>Aksan, Gökhan ; Gedikli, Ömer ; Keskin, Kudret ; Nar, Gökay ; İnci, Sinan ; Yıldız, Süleyman Sezai ; Kaplan, Özgür ; Soylu, Korhan ; Kılıçkesmez, Kadriye Orta ; Şahin, Mahmut</creator><creatorcontrib>Aksan, Gökhan ; Gedikli, Ömer ; Keskin, Kudret ; Nar, Gökay ; İnci, Sinan ; Yıldız, Süleyman Sezai ; Kaplan, Özgür ; Soylu, Korhan ; Kılıçkesmez, Kadriye Orta ; Şahin, Mahmut</creatorcontrib><description>Atherosclerosis is a complex process mediated by leukocytes, macrophages and various inflammatory markers. Galectin-3 is secreted by activated macrophages and is involved in cardiac fibrosis, cardiac remodeling, and inflammation. The present study aimed to determine the relationship between the presence and severity of coronary artery disease (CAD) and serum galectin-3 levels. The study included 82 patients with CAD confirmed via coronary angiography and 82 healthy participants as control group. Angiographic CAD was defined as ≥50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score; and the serum galectin-3 levels were measured via ELISA. Serum galectin-3 levels were significantly higher in the patient group with CAD than in the control group (12.96±4.92 vs 5.52±1.9 ng/mL, p&lt;0.001). In the correlation analysis, serum galectin-3 showed significant correlation with the Gensini score (r=0.715, p&lt;0.001), number of diseased vessels (r=0.752, p&lt;0.001) and serum hs-CRP level (r=0.607, p&lt;0.001). In addition, multivariate logistic regression analysis showed that the serum galectin-3 levels were significant and independent predictors of the presence of angiographic CAD (OR=3.933, 95% CI 2.395 to 6.457; p&lt;0.001). In the present study, the serum galectin-3 levels were higher in the patients with CAD than in healthy controls. Also, serum galectin-3 levels showed a significant positive correlation with the severity of CAD. An increased serum galectin-3 level may be considered an important activator and a marker of the atherosclerotic inflammatory process in CAD.</description><identifier>ISSN: 1081-5589</identifier><identifier>EISSN: 1708-8267</identifier><identifier>DOI: 10.1136/jim-2015-000041</identifier><identifier>PMID: 26912009</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Atherosclerosis ; Atherosclerosis - blood ; Biomarkers ; Biomarkers - blood ; C-Reactive Protein - metabolism ; Cardiovascular disease ; Case-Control Studies ; Coronary Angiography ; Coronary Artery Disease - blood ; Female ; Galectin 3 - blood ; Humans ; Inflammation ; Logistic Models ; Male ; Middle Aged ; Proteins ; Risk Factors</subject><ispartof>Journal of investigative medicine, 2016-03, Vol.64 (3), p.764-770</ispartof><rights>Copyright © 2016 American Federation for Medical Research</rights><rights>2016 American Federation for Medical Research</rights><rights>Copyright © 2016 American Federation for Medical Research.</rights><rights>Copyright: 2016 Copyright (c) 2016 American Federation for Medical Research</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973</citedby><cites>FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1786935320/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1786935320?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,21357,21375,27905,27906,33592,33593,33750,33751,43714,43795,73970,74059</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26912009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aksan, Gökhan</creatorcontrib><creatorcontrib>Gedikli, Ömer</creatorcontrib><creatorcontrib>Keskin, Kudret</creatorcontrib><creatorcontrib>Nar, Gökay</creatorcontrib><creatorcontrib>İnci, Sinan</creatorcontrib><creatorcontrib>Yıldız, Süleyman Sezai</creatorcontrib><creatorcontrib>Kaplan, Özgür</creatorcontrib><creatorcontrib>Soylu, Korhan</creatorcontrib><creatorcontrib>Kılıçkesmez, Kadriye Orta</creatorcontrib><creatorcontrib>Şahin, Mahmut</creatorcontrib><title>Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?</title><title>Journal of investigative medicine</title><addtitle>J Investig Med</addtitle><description>Atherosclerosis is a complex process mediated by leukocytes, macrophages and various inflammatory markers. Galectin-3 is secreted by activated macrophages and is involved in cardiac fibrosis, cardiac remodeling, and inflammation. The present study aimed to determine the relationship between the presence and severity of coronary artery disease (CAD) and serum galectin-3 levels. The study included 82 patients with CAD confirmed via coronary angiography and 82 healthy participants as control group. Angiographic CAD was defined as ≥50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score; and the serum galectin-3 levels were measured via ELISA. Serum galectin-3 levels were significantly higher in the patient group with CAD than in the control group (12.96±4.92 vs 5.52±1.9 ng/mL, p&lt;0.001). In the correlation analysis, serum galectin-3 showed significant correlation with the Gensini score (r=0.715, p&lt;0.001), number of diseased vessels (r=0.752, p&lt;0.001) and serum hs-CRP level (r=0.607, p&lt;0.001). In addition, multivariate logistic regression analysis showed that the serum galectin-3 levels were significant and independent predictors of the presence of angiographic CAD (OR=3.933, 95% CI 2.395 to 6.457; p&lt;0.001). In the present study, the serum galectin-3 levels were higher in the patients with CAD than in healthy controls. Also, serum galectin-3 levels showed a significant positive correlation with the severity of CAD. An increased serum galectin-3 level may be considered an important activator and a marker of the atherosclerotic inflammatory process in CAD.</description><subject>Atherosclerosis</subject><subject>Atherosclerosis - blood</subject><subject>Biomarkers</subject><subject>Biomarkers - blood</subject><subject>C-Reactive Protein - metabolism</subject><subject>Cardiovascular disease</subject><subject>Case-Control Studies</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Disease - blood</subject><subject>Female</subject><subject>Galectin 3 - blood</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Proteins</subject><subject>Risk Factors</subject><issn>1081-5589</issn><issn>1708-8267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>BGRYB</sourceid><sourceid>M0O</sourceid><recordid>eNqFkMtKxDAUhoMo3tfuJOBGxDq5NGmyEhm8geBGd0JJ4ql2bJsx6Sxm50P4hD6JGTqKCGIWyQn58p_kQ2iPkhNKuRxN6jZjhIqMpJHTFbRJC6IyxWSxmmqiaCaE0htoK8YJIUwKzdbRBpOaMkL0Jnq4jvjJNOD6uss4NtjWvjXhBcJx2kwbM4fw8fbuA7a-f05V3eH-GfA0QITOAfYVdj74zoQ5Nukk-OiaxVzH0x20Vpkmwu5y3Ub3F-d346vs5vbyenx2k1muiz6zAEAcJVazR0akUMZRznPldJVTY7RSQuc5ySudM5KDs0JzbriuDLVgdMG30eGQOw3-dQaxL9s6Omga04GfxZIWUglJi0Im9OAXOvGz0KXXJUpJzQVnJFGjgXLpIzFAVU5DnbTMS0rKhfgyiS8X4stBfLqxv8yd2RYev_kv0wk4HoBonuBH0z_zjgbctpN_m38CmFuZvQ</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Aksan, Gökhan</creator><creator>Gedikli, Ömer</creator><creator>Keskin, Kudret</creator><creator>Nar, Gökay</creator><creator>İnci, Sinan</creator><creator>Yıldız, Süleyman Sezai</creator><creator>Kaplan, Özgür</creator><creator>Soylu, Korhan</creator><creator>Kılıçkesmez, Kadriye Orta</creator><creator>Şahin, Mahmut</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AM</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K7.</scope><scope>K9.</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20160301</creationdate><title>Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?</title><author>Aksan, Gökhan ; Gedikli, Ömer ; Keskin, Kudret ; Nar, Gökay ; İnci, Sinan ; Yıldız, Süleyman Sezai ; Kaplan, Özgür ; Soylu, Korhan ; Kılıçkesmez, Kadriye Orta ; Şahin, Mahmut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Atherosclerosis</topic><topic>Atherosclerosis - blood</topic><topic>Biomarkers</topic><topic>Biomarkers - blood</topic><topic>C-Reactive Protein - metabolism</topic><topic>Cardiovascular disease</topic><topic>Case-Control Studies</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Disease - blood</topic><topic>Female</topic><topic>Galectin 3 - blood</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Proteins</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aksan, Gökhan</creatorcontrib><creatorcontrib>Gedikli, Ömer</creatorcontrib><creatorcontrib>Keskin, Kudret</creatorcontrib><creatorcontrib>Nar, Gökay</creatorcontrib><creatorcontrib>İnci, Sinan</creatorcontrib><creatorcontrib>Yıldız, Süleyman Sezai</creatorcontrib><creatorcontrib>Kaplan, Özgür</creatorcontrib><creatorcontrib>Soylu, Korhan</creatorcontrib><creatorcontrib>Kılıçkesmez, Kadriye Orta</creatorcontrib><creatorcontrib>Şahin, Mahmut</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Criminology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Criminal Justice Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aksan, Gökhan</au><au>Gedikli, Ömer</au><au>Keskin, Kudret</au><au>Nar, Gökay</au><au>İnci, Sinan</au><au>Yıldız, Süleyman Sezai</au><au>Kaplan, Özgür</au><au>Soylu, Korhan</au><au>Kılıçkesmez, Kadriye Orta</au><au>Şahin, Mahmut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?</atitle><jtitle>Journal of investigative medicine</jtitle><addtitle>J Investig Med</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>64</volume><issue>3</issue><spage>764</spage><epage>770</epage><pages>764-770</pages><issn>1081-5589</issn><eissn>1708-8267</eissn><abstract>Atherosclerosis is a complex process mediated by leukocytes, macrophages and various inflammatory markers. Galectin-3 is secreted by activated macrophages and is involved in cardiac fibrosis, cardiac remodeling, and inflammation. The present study aimed to determine the relationship between the presence and severity of coronary artery disease (CAD) and serum galectin-3 levels. The study included 82 patients with CAD confirmed via coronary angiography and 82 healthy participants as control group. Angiographic CAD was defined as ≥50% luminal diameter stenosis of at least one major epicardial coronary artery. The severity of CAD was determined by the Gensini score; and the serum galectin-3 levels were measured via ELISA. Serum galectin-3 levels were significantly higher in the patient group with CAD than in the control group (12.96±4.92 vs 5.52±1.9 ng/mL, p&lt;0.001). In the correlation analysis, serum galectin-3 showed significant correlation with the Gensini score (r=0.715, p&lt;0.001), number of diseased vessels (r=0.752, p&lt;0.001) and serum hs-CRP level (r=0.607, p&lt;0.001). In addition, multivariate logistic regression analysis showed that the serum galectin-3 levels were significant and independent predictors of the presence of angiographic CAD (OR=3.933, 95% CI 2.395 to 6.457; p&lt;0.001). In the present study, the serum galectin-3 levels were higher in the patients with CAD than in healthy controls. Also, serum galectin-3 levels showed a significant positive correlation with the severity of CAD. An increased serum galectin-3 level may be considered an important activator and a marker of the atherosclerotic inflammatory process in CAD.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>26912009</pmid><doi>10.1136/jim-2015-000041</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1081-5589
ispartof Journal of investigative medicine, 2016-03, Vol.64 (3), p.764-770
issn 1081-5589
1708-8267
language eng
recordid cdi_proquest_miscellaneous_1768561776
source Criminology Collection; Social Science Premium Collection (Proquest) (PQ_SDU_P3)
subjects Atherosclerosis
Atherosclerosis - blood
Biomarkers
Biomarkers - blood
C-Reactive Protein - metabolism
Cardiovascular disease
Case-Control Studies
Coronary Angiography
Coronary Artery Disease - blood
Female
Galectin 3 - blood
Humans
Inflammation
Logistic Models
Male
Middle Aged
Proteins
Risk Factors
title Is galectin-3 a biomarker, a player—or both—in the presence of coronary atherosclerosis?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A56%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20galectin-3%20a%20biomarker,%20a%20player%E2%80%94or%20both%E2%80%94in%20the%20presence%20of%20coronary%20atherosclerosis?&rft.jtitle=Journal%20of%20investigative%20medicine&rft.au=Aksan,%20G%C3%B6khan&rft.date=2016-03-01&rft.volume=64&rft.issue=3&rft.spage=764&rft.epage=770&rft.pages=764-770&rft.issn=1081-5589&rft.eissn=1708-8267&rft_id=info:doi/10.1136/jim-2015-000041&rft_dat=%3Cproquest_cross%3E1768561776%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b397t-beee0c10b92d20658ac13348c9f41aa988594404f94204ecb5933a39fa1bea973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1786935320&rft_id=info:pmid/26912009&rft_sage_id=10.1136_jim-2015-000041&rfr_iscdi=true